Products and Services

Are you interested in Cell Line Development, the development of a New Biological Drug, Biosimilar or an improved bioprocess?

We will bring your project faster to success! UGA Biopharma has longstanding expertise and know-how in cell line development, bioprocess optimization, downstream development and analytics as well as media and feed development. This makes us to an ideal partner for your development projects.

UGA Biopharma - The start has to be right!

 

Ready To Use Biosimilar Cell Lines read more

Adalimumab Biosimilar (limited use only*)           

Full package ready for sales now: 

Research Cell Bank (RCB) including safety testing 

Optimized fermentation process (USP) 

Optimized downstream purification process (DSP) and analytics 

Including proof of activity of the expressed protein 



If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Aflibercept Biosimilar (limited use only*)           

Aflibercept is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

 

Alirocumab Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Anakinra Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Bevacizumab Biosimilar (limited use only*)           

Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Certolizumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Darbepoetin alfa Biosimilar (limited use only*)           

Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Dupilumab Biosimilar (limited use only*)           
An outstanding product concentration higher than 7 g/L could be reached during the Dupilumab development project! The first CHOice® Medium works very well for Dupilumab clones.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Eculizumab Biosimilar (limited use only*)           

Very good biosimilarity achieved in a challenging Eculizumab development project (IgG2/4 hybrid antibody). 


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Etanercept Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Ipilimumab Biosimilar (limited use only*)           
Typical charge profil of ther reference medical product of Ipilimumab.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Laronidase Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Mepolizumab Biosimilar (limited use only*)           

This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Natalizumab Biosimilar (limited use only*)           
The primary structure of a biosimilar has to be identical to the originator molecule. The result of the peptide mapping of the Natalizumab biosimilar is depicted here.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Nivolumab Biosimilar (limited use only*)           
A product concentration over 3 g/L has been obtained during a Nivolumab consistency run in stirred bioreactors.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Omalizumab Biosimilar (limited use only*)           
A product concentration of 3 g/L has been obtained during the Omalizumab biosimilar development project.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Panitumumab Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
 
Pembrolizumab Biosimilar (limited use only*)           
Pembrolizumab (IgG4) biosimilar development project has been finalized in a very short time line – according to the High Speed Workflow of UGA Biopharma!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Pertuzumab Biosimilar (limited use only*)           
Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Under Development

Imiglucerase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Dulaglutide Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Elosulfase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Erenumab Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Galsulfase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Idursulfase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   

Disclaimer

*Limited use only: Until the expiration of the patent and potential supplementary protection certificates related to the reference medical product the client must not (i) produce, offer or put on the market the respective medical product or possess the product for such purposes, or (ii) use the cell lines or products offered by UGA Biopharma except for experimental use or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act.           





Contact

UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900